Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference Apr 24, 2019
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board Apr 11, 2019
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights Mar 19, 2019
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease Mar 14, 2019
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019 Mar 7, 2019
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis Feb 25, 2019
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City Feb 20, 2019
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome Jan 22, 2019
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome Jan 21, 2019
